|
Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory acute myeloid leukemia. Hemogenyx Pharmaceuticals is a London-headquartered biopharmaceutical company focused on treatments for blood diseases. It said the patient treated was the final participant in the first dose adult cohort, with the treatment made possible following special permission from the US Food & Drug Administration to proceed under exceptional circumstances. Shares in the company climbed 9.8% to 156.22 pence on Friday afternoon in London. Hemogenyx Pharmaceuticals said the completion of the first adult dose cohort marked a ‘pivotal milestone’ in the trial. Should no dose-limiting toxicities occur, it expects to advance the second adult cohort at twice the initial dose, and begin recruitment for the paediatric arm of the trial. Hemogenyx Pharmaceuticals noted that the first two patients treated with HG-CT-1 ‘remain alive at six months and three months post-treatment, respectively.’ ‘Completing the first adult dose cohort is a major achievement in our Phase I trial of HG-CT-1. I am proud of our team’s persistence in working with the FDA to obtain the necessary clearance to treat this patient,’ said Vladislav Sandler, co-founder & chief executive of Hemogenyx Pharmaceuticals. ‘With this milestone reached, we are well positioned to move into the higher-dose cohort and to open our paediatric arm, advancing our mission to deliver transformative therapies for AML patients of all ages,’ Sandler continued. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
